RxDoctor Payments Data

Noel Hunt, MD

Gastroenterology · Tupelo, MSNPI 1881603538

Payments from drug & device makers

$2,667in general payments, 2019–2025

Across 162 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$980
  • Sanofi$246
  • Boston Scientific$220
  • Johnson & Johnson$212
  • Intercept Pharmaceuticals, Inc.$165
  • Gilead$151
  • plus $692 from 18 others

What the payments were for

  • Food & beverage$2,56796%
  • Gifts$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,667 in reported general payments places this provider in the 35th percentile of 127 gastroenterology providers in Mississippi.

See all gastroenterology providers in Mississippi

Medicare billing

Part B allowed, 2024
$242,069
Medicare patients
965
Services billed
4,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$339,608
RinvoqUpadacitinib15$157,357
CreonLipase/Protease/Amylase20$74,757
LinzessLinaclotide36$34,916
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates195$12,716
TrulancePlecanatide19$11,521
Dexlansoprazole DrDexlansoprazole26$5,265
Ursodiol25$4,745
SutabSod Sulf/Pot Chloride/Mag Sulf17$2,770
Pantoprazole Sodium289$2,488
Famotidine229$2,449
Esomeprazole Magnesium37$2,113
Omeprazole202$1,681
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag12$1,379
CholestyramineCholestyramine (With Sugar)20$1,372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$212$339,60812 claims
AbbVieRinvoq, Creon, Linzess$980$267,03071 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$75$11,52119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 127 gastroenterology providers in Mississippi.

Other gastroenterology in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →